6:11 PM
Feb 03, 2009
 |  BC Extra  |  Clinical News

Safinamide meets PD endpoint

Newron (SWX:NWRN) and Merck KGaA (Xetra:MRK) said top-line data showed that both 50 and 100 mg oral safinamide as adjunct therapy to levodopa met the primary endpoint...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >